BeiGene, Ltd.
BeiGene, Ltd. (BGNE) Stock Competitors & Peer Comparison
See (BGNE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| VRTX | $388.94 | -1.56% | 99.7B | 27.63 | $14.07 | N/A |
| REGN | $572.38 | -2.90% | 59.6B | 14.43 | $39.67 | +0.46% |
| ALNY | $443.64 | -2.36% | 58.2B | -181.08 | -$2.45 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $677.32 | +2.62% | 41.4B | 34.43 | $19.67 | N/A |
| BNTX | $105.07 | -5.24% | 25.3B | -63.30 | -$1.66 | N/A |
| SMMT | $26.27 | +0.27% | 19.5B | -26.01 | -$1.01 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
| INCY | $84.76 | -0.33% | 16.6B | 20.04 | $4.23 | N/A |
Stock Comparison
BGNE vs VRTX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, VRTX has a market cap of 99.7B. Regarding current trading prices, BGNE is priced at $184.71, while VRTX trades at $388.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas VRTX's P/E ratio is 27.63. In terms of profitability, BGNE's ROE is -0.05%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, BGNE is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check VRTX's competition here
BGNE vs REGN Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, REGN has a market cap of 59.6B. Regarding current trading prices, BGNE is priced at $184.71, while REGN trades at $572.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas REGN's P/E ratio is 14.43. In terms of profitability, BGNE's ROE is -0.05%, compared to REGN's ROE of +0.15%. Regarding short-term risk, BGNE is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check REGN's competition here
BGNE vs ALNY Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALNY has a market cap of 58.2B. Regarding current trading prices, BGNE is priced at $184.71, while ALNY trades at $443.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ALNY's P/E ratio is -181.08. In terms of profitability, BGNE's ROE is -0.05%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, BGNE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ALNY's competition here
BGNE vs SGEN Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BGNE is priced at $184.71, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BGNE's ROE is -0.05%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BGNE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check SGEN's competition here
BGNE vs ARGX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ARGX has a market cap of 41.4B. Regarding current trading prices, BGNE is priced at $184.71, while ARGX trades at $677.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ARGX's P/E ratio is 34.43. In terms of profitability, BGNE's ROE is -0.05%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, BGNE is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ARGX's competition here
BGNE vs BNTX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BNTX has a market cap of 25.3B. Regarding current trading prices, BGNE is priced at $184.71, while BNTX trades at $105.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BNTX's P/E ratio is -63.30. In terms of profitability, BGNE's ROE is -0.05%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, BGNE is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BNTX's competition here
BGNE vs SMMT Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SMMT has a market cap of 19.5B. Regarding current trading prices, BGNE is priced at $184.71, while SMMT trades at $26.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SMMT's P/E ratio is -26.01. In terms of profitability, BGNE's ROE is -0.05%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, BGNE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SMMT's competition here
BGNE vs DNA-WT Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BGNE is priced at $184.71, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BGNE's ROE is -0.05%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, BGNE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check DNA-WT's competition here
BGNE vs INCY Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, INCY has a market cap of 16.6B. Regarding current trading prices, BGNE is priced at $184.71, while INCY trades at $84.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas INCY's P/E ratio is 20.04. In terms of profitability, BGNE's ROE is -0.05%, compared to INCY's ROE of +0.24%. Regarding short-term risk, BGNE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check INCY's competition here
BGNE vs RPRX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RPRX has a market cap of 15.6B. Regarding current trading prices, BGNE is priced at $184.71, while RPRX trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RPRX's P/E ratio is 15.71. In terms of profitability, BGNE's ROE is -0.05%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, BGNE is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RPRX's competition here
BGNE vs GMAB Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, GMAB has a market cap of 15.3B. Regarding current trading prices, BGNE is priced at $184.71, while GMAB trades at $24.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas GMAB's P/E ratio is 12.60. In terms of profitability, BGNE's ROE is -0.05%, compared to GMAB's ROE of +0.28%. Regarding short-term risk, BGNE is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check GMAB's competition here
BGNE vs UTHR Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, UTHR has a market cap of 13.8B. Regarding current trading prices, BGNE is priced at $184.71, while UTHR trades at $305.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas UTHR's P/E ratio is 11.91. In terms of profitability, BGNE's ROE is -0.05%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BGNE is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check UTHR's competition here
BGNE vs KRTX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BGNE is priced at $184.71, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BGNE's ROE is -0.05%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BGNE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check KRTX's competition here
BGNE vs ASND Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ASND has a market cap of 11.5B. Regarding current trading prices, BGNE is priced at $184.71, while ASND trades at $190.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ASND's P/E ratio is -36.05. In terms of profitability, BGNE's ROE is -0.05%, compared to ASND's ROE of +1.52%. Regarding short-term risk, BGNE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ASND's competition here
BGNE vs BMRN Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, BGNE is priced at $184.71, while BMRN trades at $58.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BMRN's P/E ratio is 17.26. In terms of profitability, BGNE's ROE is -0.05%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, BGNE is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BMRN's competition here
BGNE vs EXEL Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, EXEL has a market cap of 10.2B. Regarding current trading prices, BGNE is priced at $184.71, while EXEL trades at $37.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas EXEL's P/E ratio is 18.22. In terms of profitability, BGNE's ROE is -0.05%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, BGNE is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check EXEL's competition here
BGNE vs MRNA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRNA has a market cap of 9.9B. Regarding current trading prices, BGNE is priced at $184.71, while MRNA trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MRNA's P/E ratio is -3.38. In terms of profitability, BGNE's ROE is -0.05%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, BGNE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MRNA's competition here
BGNE vs RXDX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BGNE is priced at $184.71, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BGNE's ROE is -0.05%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BGNE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RXDX's competition here
BGNE vs MDGL Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, BGNE is priced at $184.71, while MDGL trades at $412.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MDGL's P/E ratio is -32.59. In terms of profitability, BGNE's ROE is -0.05%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, BGNE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MDGL's competition here
BGNE vs BBIO Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BBIO has a market cap of 9B. Regarding current trading prices, BGNE is priced at $184.71, while BBIO trades at $47.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BBIO's P/E ratio is -11.45. In terms of profitability, BGNE's ROE is -0.05%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, BGNE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BBIO's competition here
BGNE vs VRNA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, BGNE is priced at $184.71, while VRNA trades at $105.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas VRNA's P/E ratio is -100.59. In terms of profitability, BGNE's ROE is -0.05%, compared to VRNA's ROE of -0.39%. Regarding short-term risk, BGNE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check VRNA's competition here
BGNE vs TECH Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TECH has a market cap of 8.9B. Regarding current trading prices, BGNE is priced at $184.71, while TECH trades at $56.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TECH's P/E ratio is 123.28. In terms of profitability, BGNE's ROE is -0.05%, compared to TECH's ROE of +0.06%. Regarding short-term risk, BGNE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TECH's competition here
BGNE vs IMGN Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BGNE is priced at $184.71, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BGNE's ROE is -0.05%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, BGNE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check IMGN's competition here
BGNE vs HALO Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, BGNE is priced at $184.71, while HALO trades at $72.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas HALO's P/E ratio is 16.52. In terms of profitability, BGNE's ROE is -0.05%, compared to HALO's ROE of +1.37%. Regarding short-term risk, BGNE is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check HALO's competition here
BGNE vs BPMC Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BGNE is priced at $184.71, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BGNE's ROE is -0.05%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, BGNE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check BPMC's competition here
BGNE vs CERE Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BGNE is priced at $184.71, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CERE's P/E ratio is -16.47. In terms of profitability, BGNE's ROE is -0.05%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BGNE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CERE's competition here
BGNE vs ROIV Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, BGNE is priced at $184.71, while ROIV trades at $11.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ROIV's P/E ratio is -10.68. In terms of profitability, BGNE's ROE is -0.05%, compared to ROIV's ROE of -0.10%. Regarding short-term risk, BGNE is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ROIV's competition here
BGNE vs ROIVW Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, BGNE is priced at $184.71, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, BGNE's ROE is -0.05%, compared to ROIVW's ROE of -0.10%. Regarding short-term risk, BGNE is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ROIVW's competition here
BGNE vs JAZZ Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, JAZZ has a market cap of 7.6B. Regarding current trading prices, BGNE is priced at $184.71, while JAZZ trades at $124.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas JAZZ's P/E ratio is -17.85. In terms of profitability, BGNE's ROE is -0.05%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, BGNE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check JAZZ's competition here
BGNE vs CORT Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, BGNE is priced at $184.71, while CORT trades at $68.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CORT's P/E ratio is 61.45. In terms of profitability, BGNE's ROE is -0.05%, compared to CORT's ROE of +0.20%. Regarding short-term risk, BGNE is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CORT's competition here
BGNE vs RVMD Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RVMD has a market cap of 6.7B. Regarding current trading prices, BGNE is priced at $184.71, while RVMD trades at $35.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RVMD's P/E ratio is -7.89. In terms of profitability, BGNE's ROE is -0.05%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, BGNE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RVMD's competition here
BGNE vs IONS Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, BGNE is priced at $184.71, while IONS trades at $41.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IONS's P/E ratio is -23.76. In terms of profitability, BGNE's ROE is -0.05%, compared to IONS's ROE of -0.45%. Regarding short-term risk, BGNE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IONS's competition here
BGNE vs RYTM Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, BGNE is priced at $184.71, while RYTM trades at $99.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RYTM's P/E ratio is -32.96. In terms of profitability, BGNE's ROE is -0.05%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, BGNE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RYTM's competition here
BGNE vs RETA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BGNE is priced at $184.71, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RETA's P/E ratio is -66.29. In terms of profitability, BGNE's ROE is -0.05%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BGNE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RETA's competition here
BGNE vs ABVX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ABVX has a market cap of 5.9B. Regarding current trading prices, BGNE is priced at $184.71, while ABVX trades at $77.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ABVX's P/E ratio is -22.52. In terms of profitability, BGNE's ROE is -0.05%, compared to ABVX's ROE of -1.62%. Regarding short-term risk, BGNE is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ABVX's competition here
BGNE vs RNA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RNA has a market cap of 5.8B. Regarding current trading prices, BGNE is priced at $184.71, while RNA trades at $45.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RNA's P/E ratio is -12.72. In terms of profitability, BGNE's ROE is -0.05%, compared to RNA's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RNA's competition here
BGNE vs AXSM Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, AXSM has a market cap of 5.8B. Regarding current trading prices, BGNE is priced at $184.71, while AXSM trades at $116.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas AXSM's P/E ratio is -22.99. In terms of profitability, BGNE's ROE is -0.05%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, BGNE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AXSM's competition here
BGNE vs ABCM Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BGNE's ROE is -0.05%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BGNE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ABCM's competition here
BGNE vs ISEE Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BGNE's ROE is -0.05%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BGNE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ISEE's competition here
BGNE vs NUVL Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, BGNE is priced at $184.71, while NUVL trades at $74.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas NUVL's P/E ratio is -15.05. In terms of profitability, BGNE's ROE is -0.05%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check NUVL's competition here
BGNE vs MRUS Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, BGNE is priced at $184.71, while MRUS trades at $65.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MRUS's P/E ratio is -11.78. In terms of profitability, BGNE's ROE is -0.05%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, BGNE is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MRUS's competition here
BGNE vs CRSP Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, BGNE is priced at $184.71, while CRSP trades at $54.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CRSP's P/E ratio is -10.02. In terms of profitability, BGNE's ROE is -0.05%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, BGNE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CRSP's competition here
BGNE vs ALKS Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, BGNE is priced at $184.71, while ALKS trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ALKS's P/E ratio is 14.01. In terms of profitability, BGNE's ROE is -0.05%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, BGNE is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ALKS's competition here
BGNE vs TGTX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while TGTX trades at $28.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TGTX's P/E ratio is 75.08. In terms of profitability, BGNE's ROE is -0.05%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, BGNE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TGTX's competition here
BGNE vs ALPN Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BGNE's ROE is -0.05%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BGNE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ALPN's competition here
BGNE vs CYTK Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, BGNE is priced at $184.71, while CYTK trades at $37.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CYTK's P/E ratio is -7.23. In terms of profitability, BGNE's ROE is -0.05%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, BGNE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CYTK's competition here
BGNE vs ACAD Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, BGNE is priced at $184.71, while ACAD trades at $25.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ACAD's P/E ratio is 19.04. In terms of profitability, BGNE's ROE is -0.05%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, BGNE is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ACAD's competition here
BGNE vs KRYS Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KRYS has a market cap of 4.2B. Regarding current trading prices, BGNE is priced at $184.71, while KRYS trades at $146.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KRYS's P/E ratio is 29.83. In terms of profitability, BGNE's ROE is -0.05%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, BGNE is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KRYS's competition here
BGNE vs OPT Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BGNE is priced at $184.71, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas OPT's P/E ratio is -1.52. In terms of profitability, BGNE's ROE is -0.05%, compared to OPT's ROE of +2.60%. Regarding short-term risk, BGNE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check OPT's competition here
BGNE vs TLX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while TLX trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TLX's P/E ratio is 610.00. In terms of profitability, BGNE's ROE is -0.05%, compared to TLX's ROE of +0.10%. Regarding short-term risk, BGNE is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TLX's competition here
BGNE vs MRTX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BGNE's ROE is -0.05%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BGNE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MRTX's competition here
BGNE vs ADMA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while ADMA trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ADMA's P/E ratio is 20.01. In terms of profitability, BGNE's ROE is -0.05%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, BGNE is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ADMA's competition here
BGNE vs AAPG Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, AAPG has a market cap of 4B. Regarding current trading prices, BGNE is priced at $184.71, while AAPG trades at $43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas AAPG's P/E ratio is -21.44. In terms of profitability, BGNE's ROE is -0.05%, compared to AAPG's ROE of -0.79%. Regarding short-term risk, BGNE is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AAPG's competition here
BGNE vs PCVX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, PCVX has a market cap of 4B. Regarding current trading prices, BGNE is priced at $184.71, while PCVX trades at $30.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas PCVX's P/E ratio is -7.41. In terms of profitability, BGNE's ROE is -0.05%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, BGNE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PCVX's competition here
BGNE vs PTCT Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, BGNE is priced at $184.71, while PTCT trades at $49.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas PTCT's P/E ratio is 6.99. In terms of profitability, BGNE's ROE is -0.05%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, BGNE is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PTCT's competition here
BGNE vs ACLX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while ACLX trades at $68.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ACLX's P/E ratio is -20.09. In terms of profitability, BGNE's ROE is -0.05%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, BGNE is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ACLX's competition here
BGNE vs AKRO Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, AKRO has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while AKRO trades at $47.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas AKRO's P/E ratio is -12.34. In terms of profitability, BGNE's ROE is -0.05%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AKRO's competition here
BGNE vs RYZB Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BGNE's ROE is -0.05%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BGNE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RYZB's competition here
BGNE vs ZLAB Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ZLAB has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while ZLAB trades at $34.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ZLAB's P/E ratio is -17.01. In terms of profitability, BGNE's ROE is -0.05%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, BGNE is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ZLAB's competition here
BGNE vs CBAY Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BGNE's ROE is -0.05%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BGNE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CBAY's competition here
BGNE vs MIRM Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MIRM has a market cap of 3.6B. Regarding current trading prices, BGNE is priced at $184.71, while MIRM trades at $71.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MIRM's P/E ratio is -59.35. In terms of profitability, BGNE's ROE is -0.05%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, BGNE is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MIRM's competition here
BGNE vs SWTX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BGNE's ROE is -0.05%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, BGNE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check SWTX's competition here
BGNE vs PTGX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while PTGX trades at $56.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas PTGX's P/E ratio is 77.92. In terms of profitability, BGNE's ROE is -0.05%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, BGNE is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PTGX's competition here
BGNE vs SLNO Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SLNO has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while SLNO trades at $66.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SLNO's P/E ratio is -15.75. In terms of profitability, BGNE's ROE is -0.05%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, BGNE is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SLNO's competition here
BGNE vs APLS Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while APLS trades at $27.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas APLS's P/E ratio is -15.04. In terms of profitability, BGNE's ROE is -0.05%, compared to APLS's ROE of -1.16%. Regarding short-term risk, BGNE is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check APLS's competition here
BGNE vs MLTX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while MLTX trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MLTX's P/E ratio is -19.58. In terms of profitability, BGNE's ROE is -0.05%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, BGNE is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MLTX's competition here
BGNE vs MTSR Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MTSR has a market cap of 3.4B. Regarding current trading prices, BGNE is priced at $184.71, while MTSR trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MTSR's P/E ratio is -11.12. In terms of profitability, BGNE's ROE is -0.05%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, BGNE is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MTSR's competition here
BGNE vs SRRK Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, SRRK has a market cap of 3.2B. Regarding current trading prices, BGNE is priced at $184.71, while SRRK trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas SRRK's P/E ratio is -11.41. In terms of profitability, BGNE's ROE is -0.05%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, BGNE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SRRK's competition here
BGNE vs LEGN Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, BGNE is priced at $184.71, while LEGN trades at $34.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas LEGN's P/E ratio is -19.44. In terms of profitability, BGNE's ROE is -0.05%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check LEGN's competition here
BGNE vs LGND Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, LGND has a market cap of 3.1B. Regarding current trading prices, BGNE is priced at $184.71, while LGND trades at $158.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas LGND's P/E ratio is -39.30. In terms of profitability, BGNE's ROE is -0.05%, compared to LGND's ROE of -0.09%. Regarding short-term risk, BGNE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check LGND's competition here
BGNE vs KYMR Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, BGNE is priced at $184.71, while KYMR trades at $41.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KYMR's P/E ratio is -11.98. In terms of profitability, BGNE's ROE is -0.05%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KYMR's competition here
BGNE vs XENE Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, XENE has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while XENE trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas XENE's P/E ratio is -10.74. In terms of profitability, BGNE's ROE is -0.05%, compared to XENE's ROE of -0.39%. Regarding short-term risk, BGNE is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check XENE's competition here
BGNE vs VKTX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, VKTX has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while VKTX trades at $25.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas VKTX's P/E ratio is -16.79. In terms of profitability, BGNE's ROE is -0.05%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, BGNE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check VKTX's competition here
BGNE vs ARWR Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, ARWR has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while ARWR trades at $20.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas ARWR's P/E ratio is -17.26. In terms of profitability, BGNE's ROE is -0.05%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, BGNE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ARWR's competition here
BGNE vs MORF Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MORF's P/E ratio is -14.88. In terms of profitability, BGNE's ROE is -0.05%, compared to MORF's ROE of -0.16%. Regarding short-term risk, BGNE is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MORF's competition here
BGNE vs MOR Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MOR's P/E ratio is -12.64. In terms of profitability, BGNE's ROE is -0.05%, compared to MOR's ROE of -1.84%. Regarding short-term risk, BGNE is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MOR's competition here
BGNE vs CRNX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, BGNE is priced at $184.71, while CRNX trades at $30.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CRNX's P/E ratio is -7.34. In terms of profitability, BGNE's ROE is -0.05%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CRNX's competition here
BGNE vs RARE Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, RARE has a market cap of 2.8B. Regarding current trading prices, BGNE is priced at $184.71, while RARE trades at $29.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas RARE's P/E ratio is -5.34. In terms of profitability, BGNE's ROE is -0.05%, compared to RARE's ROE of -2.37%. Regarding short-term risk, BGNE is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RARE's competition here
BGNE vs NAMS Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, BGNE is priced at $184.71, while NAMS trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas NAMS's P/E ratio is -15.53. In terms of profitability, BGNE's ROE is -0.05%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, BGNE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check NAMS's competition here
BGNE vs KDNY Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, BGNE is priced at $184.71, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KDNY's P/E ratio is -12.47. In terms of profitability, BGNE's ROE is -0.05%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, BGNE is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check KDNY's competition here
BGNE vs MYOV Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, BGNE is priced at $184.71, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas MYOV's P/E ratio is -14.05. In terms of profitability, BGNE's ROE is -0.05%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, BGNE is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MYOV's competition here
BGNE vs IMVT Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, BGNE is priced at $184.71, while IMVT trades at $14.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IMVT's P/E ratio is -5.24. In terms of profitability, BGNE's ROE is -0.05%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, BGNE is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IMVT's competition here
BGNE vs CPRX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, BGNE is priced at $184.71, while CPRX trades at $20.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CPRX's P/E ratio is 12.50. In terms of profitability, BGNE's ROE is -0.05%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, BGNE is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CPRX's competition here
BGNE vs KNSA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, BGNE is priced at $184.71, while KNSA trades at $33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas KNSA's P/E ratio is 660.80. In terms of profitability, BGNE's ROE is -0.05%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, BGNE is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KNSA's competition here
BGNE vs TARS Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, TARS has a market cap of 2.4B. Regarding current trading prices, BGNE is priced at $184.71, while TARS trades at $56.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas TARS's P/E ratio is -24.72. In terms of profitability, BGNE's ROE is -0.05%, compared to TARS's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TARS's competition here
BGNE vs PRVB Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, BGNE is priced at $184.71, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas PRVB's P/E ratio is -16.43. In terms of profitability, BGNE's ROE is -0.05%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, BGNE is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check PRVB's competition here
BGNE vs LBPH Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas LBPH's P/E ratio is -26.66. In terms of profitability, BGNE's ROE is -0.05%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, BGNE is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check LBPH's competition here
BGNE vs VCYT Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, VCYT has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while VCYT trades at $29.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas VCYT's P/E ratio is 86.91. In terms of profitability, BGNE's ROE is -0.05%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, BGNE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check VCYT's competition here
BGNE vs FOLD Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while FOLD trades at $7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas FOLD's P/E ratio is -62.33. In terms of profitability, BGNE's ROE is -0.05%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, BGNE is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check FOLD's competition here
BGNE vs CNTA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while CNTA trades at $17.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CNTA's P/E ratio is -9.19. In terms of profitability, BGNE's ROE is -0.05%, compared to CNTA's ROE of -0.56%. Regarding short-term risk, BGNE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CNTA's competition here
BGNE vs DNLI Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, DNLI has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while DNLI trades at $15.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas DNLI's P/E ratio is -5.54. In terms of profitability, BGNE's ROE is -0.05%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, BGNE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check DNLI's competition here
BGNE vs DICE Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas DICE's P/E ratio is -21.91. In terms of profitability, BGNE's ROE is -0.05%, compared to DICE's ROE of +0.56%. Regarding short-term risk, BGNE is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check DICE's competition here
BGNE vs LQDA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, LQDA has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while LQDA trades at $26.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas LQDA's P/E ratio is -14.42. In terms of profitability, BGNE's ROE is -0.05%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, BGNE is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check LQDA's competition here
BGNE vs APGE Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while APGE trades at $36.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas APGE's P/E ratio is -8.92. In terms of profitability, BGNE's ROE is -0.05%, compared to APGE's ROE of -0.23%. Regarding short-term risk, BGNE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check APGE's competition here
BGNE vs IDYA Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while IDYA trades at $24.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IDYA's P/E ratio is -6.43. In terms of profitability, BGNE's ROE is -0.05%, compared to IDYA's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IDYA's competition here
BGNE vs AGIO Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while AGIO trades at $37.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas AGIO's P/E ratio is 3.30. In terms of profitability, BGNE's ROE is -0.05%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, BGNE is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AGIO's competition here
BGNE vs HRMY Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, HRMY has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while HRMY trades at $37.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas HRMY's P/E ratio is 12.07. In terms of profitability, BGNE's ROE is -0.05%, compared to HRMY's ROE of +0.26%. Regarding short-term risk, BGNE is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check HRMY's competition here
BGNE vs CALT Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas CALT's P/E ratio is -22.73. In terms of profitability, BGNE's ROE is -0.05%, compared to CALT's ROE of -1.67%. Regarding short-term risk, BGNE is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CALT's competition here
BGNE vs IBRX Comparison August 2025
BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGNE stands at 20.2B. In comparison, IBRX has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while IBRX trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGNE currently has a P/E ratio of -22.55, whereas IBRX's P/E ratio is -4.69. In terms of profitability, BGNE's ROE is -0.05%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, BGNE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IBRX's competition here